About this trial
The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.
Eligibility criteria
Qualifiers
Both sexes
Over 18 years of age;
Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
Participants who are asymptomatic or have angina limited to functional class III will be considered;
Disqualifiers
Unstable Coronary Artery Disease;
Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;
Unstable angina;
NYHA functional class III or higher;
Trial design
Treatments tested in this trial
- Propolis + Royal Jelly
- Placebo
Treatment groups
Sponsors and collaborators
Universidade Federal Fluminense
Lead sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collaborator
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Collaborator